Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "herceptin"

Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

Mylan N.V. MYL and partner Biocon Ltd. announced that the FDA had accepted their Biologics License Application (BLA) for a biosimilar version of Roche Holding AG's RHHBY cancer drug, Herceptin (trastuzumab), MYL-1401O. Shares of Mylan have ... Yahoo! Canada, 4 days ago

40 images for herceptin, 4 days ago
Nasdaq, 4 days ago
Nasdaq, 4 days ago
Nasdaq, 2 weeks ago
Cancer Therapy Advisor, 1 month ago
FiercePharma, 1 month ago
Ecancer Medicalscience, 1 month ago, 1 month ago
Libya News Today, 1 month ago
Nasdaq, 1 month ago

AI Neither Adds nor Detracts From Chemo in This Setting

SAN ANTONIO — The addition of estrogen deprivation therapy to neoadjuvant chemotherapy plus trastuzumab ( Herceptin , Genentech) and pertuzumab ( Perjeta , Genentech) in patients with hormone receptor (HR)positive, human epidermal growth factor ...
 General Medicine eJournal1 month ago No boost in pCR from neoadjuvant estrogen deprivation  PM 3601 month ago ResearchDx/PacificDx to Present High-Resolution HER2 Testing Data at the San Antonio Breast Cancer Symposium  SSUChronicle.com1 month ago San Antonio Breast Cancer Symposium (SABCS) 2016  Dermatology Online Journal1 month ago

Protecting Hearts From Herceptin: MANTICORE Data 'Unclear'

 Medscape1 month ago

Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight

LONDON, Dec. 7, 2016 /PRNewswire/ -- " " report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be ...
 Yahoo! Finance1 month ago

Pfizer's Herceptin biosimilar candidate successful in late-stage study

A Phase 3 clinical trial, REFLECTIONS B3271002 , comparing the safety and efficacy of Pfizer's (NYSE: PFE ) biosimilar PF-05280014 to Roche's ( OTCQX:RHHBY ) Herceptin (trastuzumab) met the primary endpoint of showing equivalence as measured by ...
 Seeking Alpha1 month ago Success for Pfizer's Trastuzumab Biosimilar in Phase 3 Clinical Trials  JD Supra1 month ago Pfizer's Herceptin biosim posts 'encouraging' phase 3 data in blockbuster sales battle  FiercePharma1 month ago Pfizer's potential Herceptin biosimilar hits main goal of metastatic breast cancer study  FirstWord Pharma1 month ago

Cardiovascular Medications With Chemotherapy Reduce Heart Damage In Cancer Patients

Highlights: Certain medicines like Herceptin for breast cancer treatment may increase the risk of heart damage. Researchers find the combination of heart medications along with chemotherapy to prevent cardiovascular damage during breast cancer ...
 MedIndia1 month ago Study shows heart medications prevent cardiovascular damage during breast cancer treatment  News-Medical.Net1 month ago Drugs prevent heart damage during breast cancer treatment, study show  EurekAlert!1 month ago

FDA Says No To TSRO, Ablynx On Track, MYL Leads In Herceptin Biosim Race In U.S.

Vemlidy becomes the first new treatment for chronic hepatitis B infection to be approved in the European Union in nearly a decade. The drug was approved by the FDA on November 10, 2016 for the treatment of chronic HBV infection in adults with ...
 Nasdaq4 days ago

ONCOLOGY DRUG REPORT FEATURING HERCEPTIN & TRASTUZUMAB : 2006-2015 Analysis & 2016-2021 Expectations - Research and Markets

Research and Markets has announced the addition of the "Oncology Drug Report - Herceptin - Trastuzumab - 2006-2015 Analysis; 2016-2021 Expectations" report to their offering. Herceptin (trastuzumab): 2006-2015 analysis; 2016-2021 expectations is a ...
 4 Traders1 month ago Oncology Drug Market Report  BigNews.biz1 month ago Herceptin Drug Market 2016 Overview, Trend and Analysis  Before It's News1 month ago Global LAMEA Oncology/Anti-cancer Drugs Market is expected to reach $17,072.2 million by 2021, registering a CAGR of 8.6% during the forecast period 2015 - 2021 | Market Research Report  Before It's News1 month ago

Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. PFE recently announced that its experimental biosimilar of Roche Holding AG's RHHBY breast cancer drug Herceptin has reached the primary endpoint in a pivotal study. Pfizer shares rose 1.4% in November, comparing favorably with a ...
 Zacks.com1 month ago Biosimilar Challenge To Roche's Herceptin!  Trefis1 month ago

Irresponsible or a loving daughter?

My 82 year old mom suffers from several illnesses, but the main concern is that she had cancer 5 years ago, chemo/radio/Herceptin ended about 3 years ago, she was being checked for a while but then she decided to stop. Why? Too much. Too many ...
 AgingCare.com23 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less